Guangdong Zhongsheng Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is a top 100 Chinese pharmaceutical industry enterprise that integrates drug research and development, production, and sales. It is an A-share listed company. The company implements the value of "patients' interests first", adheres to the corporate purpose of "caring for life with quality products, and serving the health of the public with quality", bases itself on ophthalmology, cardio cerebrovascular, respiration, digestion and other treatment fields, takes pharmaceutical manufacturing as the core business, adheres to the development path of R&D innovation and marketing innovation, and gradually forms a development path with innovative drugs as the development leader and traditional Chinese patent medicines and simple preparations as the business cornerstone The sustainable development business system supported by chemical generic drugs is committed to becoming a first-class pharmaceutical and health industry group in China. The company's main business covers the R&D, production and sales of traditional Chinese patent medicines and simple preparations, chemicals, Chinese medicinal materials and Chinese herbal decoction pieces, chemical APIs, as well as investment in ophthalmology related industries, covering pharmaceutical, trade, innovative R&D, ophthalmology investment and other sectors. The company has four major production bases, which are located in Dongguan, Guangzhou, Zhaoqing and Qujing. For over 40 years, the company has always kept in mind the mission and responsibility of pharmaceutical companies, never forgetting the original intention of "using medicine to benefit the world and save people", practicing the corporate value of "putting patient interests first", and actively fulfilling corporate social responsibility. The company's business situation has also been recognized by relevant departments and various sectors of society. In recent years, the company has won the titles of "Top 100 Innovative Pharmaceutical Enterprises in the Asia Pacific Region" in 2019, "Top 100 Innovative Pharmaceutical Enterprises in China", "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line", "Most Growing Enterprise in China's Pharmaceutical Industry", and "Top 100 Brand Enterprises in Chinese National Medicine", and has won over 100 national, provincial, and municipal honor awards. The company adheres to the development concept of "R&D innovation is the primary productivity", with the goal of "meeting unmet clinical needs" and "developing varieties with unique clinical value". By establishing a multi-modal and virtuous cycle R&D ecosystem, it is committed to the research and development of innovative drugs for public health and safety, as well as major chronic diseases. The company has taken a series of measures such as participating in the South China New Drug Development Center, introducing an innovation team from Guangdong Province, and strategic cooperation with WuXi KangDe and the National Respiratory Disease Clinical Medical Research Center (Academician Zhong Nanshan's team), focusing on innovative drug research and development in characteristic fields such as influenza, non-alcoholic steatohepatitis (NASH), ophthalmology, oncology, and metabolic diseases. At the same time, the company seizes the historic opportunity of generic drug consistency evaluation and national centralized procurement, and steadily promotes the work of generic drug consistency evaluation. The company has a relatively rich product pipeline and continues to support steady growth in performance. The traditional Chinese patent medicines and simple preparations compound Xueshuantong series is the original research exclusive dosage form variety, the national basic medicine catalog, the national medical insurance catalog variety, and the classic product of large variety cultivation of traditional Chinese medicine; Naoshuantong Capsule is a core product for the prevention and treatment of cardiovascular and cerebrovascular diseases based on the pathogenesis theory of "toxic damage to brain meridians", and is an exclusive variety in the national medical insurance catalog; Zhongsheng Pill is a representative product of Lingnan famous medicine. In addition, key products such as chemical products such as carboxymethyl stane oral solution, sucralfate oral suspension, cefixime dispersible tablets, and loratadine tablets are gradually forming a good product cluster echelon. The company continues to implement the business strategy of "all products, all terminals, and all channels", builds a chronic disease product line around core products, deeply cultivates the grassroots pharmaceutical market in small and medium-sized cities, increases the coverage of county terminals, innovates professional chemical technology promotion systems, empowers marketing through digital technology, and explores new business models. We believe that only with effort can there be rewards, only with innovation can there be value, only with quality can there be a market, and only with health can there be a future. Guangdong Zhongsheng Pharmaceutical Co., Ltd. will always be committed to the cause of human health and is committed to becoming a first-class pharmaceutical and health industry group in China. We strive to provide patients with health products, employees with career development platforms, and partners with collaborative and win-win opportunities, witnessing a brilliant future with health together. |
| Headquarter | Dongguan |
| Establish Date | 12/31/2001 |
| Listed Code | 002317.SZ |
| Listed Date | 12/11/2009 |
| Chairman | Chen Yonghong. |
| CEO | Chen Yonghong. |
| Website | www.zspcl.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
